On Wednesday, Sage Therapeutics, Inc. released a statement revealing that its drug candidate, Dalzanemdor, also referred to as SAGE-718, failed to meet its primary target in Phase 2 of the Precedent Study. As a result, the company has decided not to continue with further development of this potential treatment for Parkinson's disease.
The study, which was double-blinded and centered around patients suffering from mild cognitive impairment due to Parkinson's disease, failed to ascertain statistically significant differences when compared with the placebo.
Even after six weeks of dosage, Dalzanemdor did not exhibit any significant variation compared to the placebo. Of the 86 study participants, 48 experienced treatment-emergent adverse events.
